DileptДилепт
GZR-123, an experimental peptidomimetic designed from a fragment of neurotensin, a signaling peptide. Human studies included psychiatric dose-finding and a comparison with risperidone.
What the studies found
Comparison in people · 2021
Dilept versus risperidone in a 28-day psychiatric comparison
- WAIS-R digit-symbol coding
- Reported difference in change −1.90 points, favoring Dilept under the authors’ sign conventionDay 28Reported interval −3.43 to −0.36
- PANSS negative symptoms and grouped psychiatric symptoms
- No statistically significant between-group differences in reported changesDay 28
A WAIS-R coding task favored Dilept by 1.90 points in the authors’ analysis. The PANSS negative-symptom subscale showed no significant advantage over risperidone.
Study notes · methods, sources and limitations
Participants or model 25 adults aged 19–54 with schizotypal disorder or pseudoneurotic schizophrenia, as described in the paper. Dilept: 15. Risperidone: 10.
Design Active-comparator study using the PANSS negative-symptom subscale, grouped psychiatric symptoms and WAIS-R testing.
Important limitations
- Small comparison with symptom and cognitive endpoints. Benzodiazepine use complicates attribution. The paper may reuse the 15-person, 200 mg/day arm of the earlier Zakusov pilot.
Experimental and Clinical Pharmacology. 2021;84(8):3–12. · Indexed abstract
Comparison in people · 2017
Dose-ranging cognitive report from the 25-patient Dilept pilot
The report describes greater changes across WAIS measures at 200 mg/day. These 25 patients match the dose-finding cohort described in the 2020 paper.
Study notes · methods, sources and limitations
Participants or model 25 patients, mean age 33.4 ± 10.0 years, with ICD-10 F21.3. Dose groups: 5 at 60 mg/day, 5 at 120 mg/day and 15 at 200 mg/day. Seventy healthy volunteers provided reference test scores.
Design WAIS comparison within the phase II dose-finding pilot, with baseline healthy reference data.
- Cognitive measures across doses
- The authors reported larger improvements in psychomotor speed, attention and memory at 200 mg/day than at 60 or 120 mg/day.
- Treatment groups
- 5, 5 and 15 patients across the ascending doses. Seventy healthy reference participants.
Important limitations
- The healthy participants provided cognitive reference scores. They did not serve as a randomized treatment control. Dose groups were small and unequal.
Experimental and Clinical Pharmacology. 2017;80(8):8–14. · Publication record
Comparison in people · 2007
Dilept: lower anxiety scores during cold exposure
Study of multiple preparations
- Dilept · cold exposure
- State anxiety −24%; trait anxiety −19%Percentages as reported; no arm sample size, baseline score or verified between-arm effect.
Original proceedings: 86 men total across the Tabai chamber experiments.
Study notes · methods, sources and limitations
Participants or model 86 healthy men aged 18–22, considered fit for military service; Tabai climate chamber with cold, heat and simulated altitude
Design 86 healthy men aged 18–22, considered fit for military service; Tabai climate chamber with cold, heat and simulated altitude
Important limitations
- Per-arm counts, doses and reliable between-arm comparisons are unavailable. Possible overlap with related journal reports.
- Treatment allocation, masking, arm denominators and complete comparator data unavailable. The text says placebo and control measurements did not differ while printing p<0.05; this inconsistency cannot be resolved from the abstract. This report may overlap the 2007 journal reports or 2008 dissertation. The 86 participants are listed separately and excluded from the combined total.
- The outcomes are condition-specific and largely qualitative. Use the journal record for its separate tables and route details, with possible cohort overlap kept visible.
Visceral Systems and Their Regulation, conference proceedings, p. 79 · Original conference abstract
About Dilept
Names in this research collection
GZR-123
Identity / background source ↗
Research background
A neurotensin-related peptidomimetic (GZR-123), studied in a psychiatric dose-finding pilot, a risperidone comparison, animal pharmacokinetics and an occupational environment study.
More study findings
Animal research · 2009
Dilept formulation and metabolite exposure in rats
- Absolute oral bioavailability of unformulated Dilept
- Less than 1%
- Time detected in plasma after oral treatment
- Unchanged drug for at least 30 minutes. Two metabolites for more than 4 hours.
Unformulated oral Dilept had less than 1% absolute bioavailability in rats. The tablet improved oral exposure, and two metabolites remained detectable in blood for more than four hours.
Study notes · methods, sources and limitations
Participants or model Rats. The abstract does not provide group sizes.
Design HPLC–tandem mass spectrometry of Dilept and metabolites, with structural confirmation by chemical synthesis.
Important limitations
- The abstract describes the tablet’s bioavailability result as a 22% improvement without clearly defining the basis of that percentage. These are formulation-specific rat data.
Experimental and Clinical Pharmacology. 2009;72(3):16–21. · Indexed abstract
Comparison in people · 2008
Climatic chamber workload by condition
Study of multiple preparations
- Dilept · cold (n=16)
- 182 W during exposureThe author reports 12% higher than the historical untreated control.
Reported cycling work capacity in healthy men aged 20–24.
Study notes · methods, sources and limitations
Participants or model 301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.
Design Tabai climatic chamber: −10°C with 2.5 m/s airflow, +45°C at 80% humidity, or 3,000 m simulated altitude. The abstract specifies 40 minutes for cold and heat and 90 minutes at altitude within a longer chamber session.
Important limitations
- Related reports have overlapping results and group differences before exposure.
- Pre-chamber values reflect the testing protocol and are not established drug-free baselines. Small groups and multiple outcomes limit interpretation. Related 2007 journal and conference reports share investigators, treatments and chamber conditions. Matching workload means indicate overlap.
- The ledger uses the 301-person dissertation total once for these related reports.
Development and Study of New Meteoadaptogens, Kirov Military Medical Academy doctoral author abstract · Original dissertation author abstract
Animal research · 2009
Rat behavioral assays: dilept
Study of multiple preparations
- Open-field behavior
- Oleyl-Cortagen increased horizontal and vertical movement but halved hole explorationCortexin and Cerebrolysin increased horizontal movement; Dilept reduced horizontal and vertical movement.
- Noopept, Semax, Selank and Dilept · vertical activity
- Reduced vertical movements reportedCompound-specific rat behavior at the stated doses, not a measure of human alertness.
- Porsolt immobility
- Lower with Oleyl-Cortagen, Dilept and Cortexin; higher with Cerebrolysin, Semax, Cortagen and SelankThis unweighted behavior assay is distinct from loaded endurance swimming. Piracetam was inactive in the report.
Separate comparisons in an assay battery.
Study notes · methods, sources and limitations
Participants or model 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
Design 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
- Reported study exposure
- 1 mg/kg intraperitoneally in the rat study.
Important limitations
- Electrical self-stimulation and immobility do not measure athletic endurance.
- Multiple behavioral comparisons, endpoint-specific group sizes and precise uncertainties need table recovery. Deltaran is the tested DSIP-containing formulation; no result for isolated DSIP can be inferred. The 2015 dissertation used separate doses/routes; it is not confirmed as independent replication of every experiment.
- Opposing effects across assays are informative. Electrical self-stimulation and immobility are behavior readouts, and neither establishes improved human motivation or endurance.
Medical Academic Journal, 2009; publisher article 9357 · Original journal article
Observational study · 2020
[The peptide analogue of neurotensin with antipsychotic and pro-cognitive effects: results of the pilot clinical trial].
- Psychiatric and cognitive measures
- Reported favorable changes; no PANSS, CGI or WAIS-R deltas supplied
A 25-person Dilept pilot reported psychiatric and cognitive improvement, most evident at 200 mg/day; it did not provide numerical symptom-score changes in its abstract.
Study notes · methods, sources and limitations
Participants or model 25 patients with schizotypal disorder
Design 25 patients with schizotypal disorder; 14-day monotherapy phase with limited rescue phenazepam, followed by combination treatment if needed.
- Participants
- 25; mean age 33.4 ± 10.0 years
- Studied doses
- 60, 120 and 200 mg/day; strongest reported action at 200 mg/day
Important limitations
- Small pilot with permitted or add-on phenazepam. The same 25 patients are described in the 2017 cognitive report. The 2021 active comparison may reuse the 15-person high-dose arm.
- Small uncontrolled pilot with rescue and subsequent combination therapy; claims about superiority to other antipsychotics are not established by this design.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · Publication record
Comparison in people · 2007
Meteoadaptogenic properties of nootrop drugs
Study of multiple preparations
- Noopept
- Favorable psychological measures in heat and cold; physical efficiency reported in heatNo effect sizes in the publisher abstract.
- Cortexin and Vinpotropil
- Cortexin effects described in cold and hypoxia; Vinpotropil in cold and heatDistinct preparations and endpoints.
- Dilept
- Favorable psychological functional-state measures describedNo numerical comparison or group counts in the abstract.
The Academy abstract describes stressor-specific functional-state findings across four compounds, including Noopept. It emphasizes mental work capacity and heat/high-altitude adaptation.
Study notes · methods, sources and limitations
Participants or model Healthy men aged 20–24; −10°C, +45°C and hypoxia (reported pO₂ 109.9 mmHg)
Design Academy report on cold, heat and hypobaric hypoxia, with cohort overlap unresolved.
Important limitations
- The current publisher record says 2007, issue 4, pp. 61–66; later bibliographies cite 2008. Original issue verification remains open. This abstract differs from the Eksp Klin Farmakol summary, including the Cortexin/cold account. Differences are preserved pending table-level review. Possible cohort overlap with the 2007 paper; not independent replication.
- Related to the 86-man and 127-man reports. Avoid pooling or importing their doses and estimates.
Bulletin of the Russian Military Medical Academy. No. 4:61–66; date discrepancy noted · Bibliographic lead
Performance research in context
- Compound class
- Environmental nootropic research
- Research collection
- Related nootropics & combinations · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Psychiatric dose-finding pilot and a risperidone comparison, with potential reuse of the high-dose arm
Study methods
Pilot monotherapy/add-on design, rodent studies and historical environmental comparisons
Independent replication
The 2017 and 2020 papers describe the same pilot cohort. The 2021 comparison may reuse its 15-person high-dose arm.
Source access
Original Russian journal PDF; selected methods checked
Safety evidence
Human long-term safety and operational protection not established
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Comparison in people · 2021
Dilept versus risperidone in a 28-day psychiatric comparison
A WAIS-R coding task favored Dilept by 1.90 points in the authors’ analysis. The PANSS negative-symptom subscale showed no significant advantage over risperidone.
Study notes and original source
Dilept versus risperidone in a 28-day psychiatric comparison
I. O. Bogdanova, T. S. Syunyakov, G. G. Neznamov, A. A. Chepelyuk, T. V. Kovalenok, O. A. Dorofeeva · Experimental and Clinical Pharmacology. 2021;84(8):3–12.
A WAIS-R coding task favored Dilept by 1.90 points in the authors’ analysis. The PANSS negative-symptom subscale showed no significant advantage over risperidone.
Results and tables
Reported findings and study design
Active-comparator study using the PANSS negative-symptom subscale, grouped psychiatric symptoms and WAIS-R testing.
Population or model 25 adults aged 19–54 with schizotypal disorder or pseudoneurotic schizophrenia, as described in the paper. Dilept: 15. Risperidone: 10.
Dose, route and schedule
Dilept 200 mg/day or risperidone 2 mg/day for 28 days. Phenazepam up to 2 mg was permitted as needed during days 1–14. From day 15, the report describes combinations with 0.5–2 mg of phenazepam.
Protocol source ↗ · Original journal abstract and comparison with the group’s 2017 and 2020 reports.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| WAIS-R digit-symbol coding | Reported difference in change −1.90 points, favoring Dilept under the authors’ sign convention | Day 28 · Reported interval −3.43 to −0.36 |
| PANSS negative symptoms and grouped psychiatric symptoms | No statistically significant between-group differences in reported changes | Day 28 |
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- 25 adults aged 19–54 with schizotypal disorder or pseudoneurotic schizophrenia, as described in the paper. Dilept: 15. Risperidone: 10.
- Source reviewed
- Original journal abstract and comparison with the group’s 2017 and 2020 reports.
Study limitations
- Small comparison with symptom and cognitive endpoints. Benzodiazepine use complicates attribution. The paper may reuse the 15-person, 200 mg/day arm of the earlier Zakusov pilot.
Reviewed 2026-11-15.
Comparison in people · 2017
Dose-ranging cognitive report from the 25-patient Dilept pilot
The report describes greater changes across WAIS measures at 200 mg/day. These 25 patients match the dose-finding cohort described in the 2020 paper.
Study notes and original source
Dose-ranging cognitive report from the 25-patient Dilept pilot
T. V. Kovalenok, A. A. Shabanova, I. O. Bogdanova, T. S. Syunyakov, N. Y. Ivashkina, N. G. Bogdan, G. G. Neznamov · Experimental and Clinical Pharmacology. 2017;80(8):8–14.
The report describes greater changes across WAIS measures at 200 mg/day. These 25 patients match the dose-finding cohort described in the 2020 paper.
Results and tables
Reported findings and study design
WAIS comparison within the phase II dose-finding pilot, with baseline healthy reference data.
Dose, route and schedule
Dilept at 60, 120 or 200 mg/day for 28 days. Nineteen patients received phenazepam 0.5–2 mg/day starting on day 15.
Protocol source ↗ · Original journal PDF and cross-check against the 2020 pilot cohort.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cognitive measures across doses | The authors reported larger improvements in psychomotor speed, attention and memory at 200 mg/day than at 60 or 120 mg/day. | |
| Treatment groups | 5, 5 and 15 patients across the ascending doses. Seventy healthy reference participants. |
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- 25 patients, mean age 33.4 ± 10.0 years, with ICD-10 F21.3. Dose groups: 5 at 60 mg/day, 5 at 120 mg/day and 15 at 200 mg/day. Seventy healthy volunteers provided reference test scores.
- Source reviewed
- Original journal PDF and cross-check against the 2020 pilot cohort.
Study limitations
- The healthy participants provided cognitive reference scores. They did not serve as a randomized treatment control. Dose groups were small and unequal.
Reviewed 2026-11-15.
Animal research · 2009
Dilept formulation and metabolite exposure in rats
Unformulated oral Dilept had less than 1% absolute bioavailability in rats. The tablet improved oral exposure, and two metabolites remained detectable in blood for more than four hours.
Study notes and original source
Dilept formulation and metabolite exposure in rats
V. P. Zherdev, S. S. Boiko, N. V. Mesonzhnik, S. A. Appolonova, G. N. Rodchenkov, R. U. Ostrovskaya, T. A. Gudasheva, S. B. Seredenin · Experimental and Clinical Pharmacology. 2009;72(3):16–21.
Unformulated oral Dilept had less than 1% absolute bioavailability in rats. The tablet improved oral exposure, and two metabolites remained detectable in blood for more than four hours.
Results and tables
Reported findings and study design
HPLC–tandem mass spectrometry of Dilept and metabolites, with structural confirmation by chemical synthesis.
Population or model Rats. The abstract does not provide group sizes.
Dose, route and schedule
Investigators compared oral and intravenous administration and reported an oral tablet dose of 200 mg/kg. The abstract does not specify the other arm doses.
Protocol source ↗ · Original indexed English abstract and pharmacokinetic findings.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Absolute oral bioavailability of unformulated Dilept | Less than 1% | |
| Time detected in plasma after oral treatment | Unchanged drug for at least 30 minutes. Two metabolites for more than 4 hours. |
Source for these results ↗ · Reviewed 2026-11-15
- Population / setting
- Rats. The abstract does not provide group sizes.
- Source reviewed
- Original indexed English abstract and pharmacokinetic findings.
Study limitations
- The abstract describes the tablet’s bioavailability result as a 22% improvement without clearly defining the basis of that percentage. These are formulation-specific rat data.
Reviewed 2026-11-15.
Comparison in people · 2008
Ganapolsky climate chambers: Cortexin, Noopept and related comparators
Reported cycling work capacity in healthy men aged 20–24.
Study notes and original source
Ganapolsky climate chambers: Cortexin, Noopept and related comparators
· Original dissertation author abstract
Format: Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending. · Reviewed: Reported methods, results and evidence limitations
V. P. Ganapolsky · Development and Study of New Meteoadaptogens, Kirov Military Medical Academy doctoral author abstract
In cold, Cortexin participants averaged 210 W versus 162 W with placebo. In heat, Noopept averaged 188 W versus 152 W with placebo.
Results and tables
Reported findings and study design
In cold, Cortexin participants averaged 210 W versus 162 W with placebo. In heat, Noopept averaged 188 W versus 152 W with placebo.
Tabai climatic chamber: −10°C with 2.5 m/s airflow, +45°C at 80% humidity, or 3,000 m simulated altitude. The abstract specifies 40 minutes for cold and heat and 90 minutes at altitude within a longer chamber session.
Population or model 301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.
Dose, route and schedule
Intranasal amounts in the author abstract: Cortexin 0.5 mg, Noopept 0.1 mg, Cerebrolysin 43 mg, Dilept 0.1 mg, Semax 0.2 mg and Deltaran 20 mg. Oral Vinpotropil contained piracetam 400 mg and vinpocetine 5 mg. Arms and testing series differ.
Protocol source ↗ · Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cortexin · cold (n=17) | 155 → 210 W vs 159 → 162 W with placebo | Before chamber to during exposure; the 210 W mean is marked p<0.05 versus placebo and historical controls. |
| Noopept · heat (n=18) | 182 → 188 W vs 164 → 152 W with placebo | Before chamber to during exposure; the 188 W mean is marked p<0.05 versus placebo. |
| Cortexin · simulated altitude | 170 → 170 W vs 162 → 154 W with placebo | |
| Cerebrolysin · heat (n=17) | 194 → 138 W vs 164 → 152 W with placebo | |
| Dilept · cold (n=16) | 182 W during exposure | The author reports 12% higher than the historical untreated control. |
| Semax · cold (n=17) | 195 → 161 W | Separate comparison. The in-chamber group mean was near control. |
| Deltaran · cold (n=18) | 196 → 217 W | Separate comparison. The author reports a significant increase from the pre-chamber measure. |
Selected in-chamber PWC₁₇₀ means (W)
| Group | Cold | Heat | Simulated altitude |
|---|---|---|---|
| Cortexin (n=17) | 210 | 155 | 170 |
| Noopept (n=18) | 189 | 188 | 197 |
| Cerebrolysin (n=17) | 157 | 138 | 152 |
| Placebo (n=9) | 162 | 152 | 154 |
PWC₁₇₀ is the cycling workload at 170 beats/min. These are descriptive group means.
The ledger uses the 301-person dissertation total once for these related reports.
Source for these results ↗ · Reviewed 2026-11-17
- Population / setting
- 301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.
- Source reviewed
- Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.
Study limitations
- Pre-chamber values reflect the testing protocol and are not established drug-free baselines. Small groups and multiple outcomes limit interpretation.
- Related 2007 journal and conference reports share investigators, treatments and chamber conditions. Matching workload means indicate overlap.
Reviewed 2026-11-17.
Comparison in people · 2007
Ganapolsky’s 86-man climate-chamber conference report
Original proceedings: 86 men total across the Tabai chamber experiments.
Study notes and original source
Ganapolsky’s 86-man climate-chamber conference report
· Original conference abstract
Format: Original proceedings PDF, printed p. 79 · Reviewed: Reported methods, results and evidence limitations
V. P. Ganapolsky, P. V. Aleksandrov, A. A. Elistratov · Visceral Systems and Their Regulation, conference proceedings, p. 79
The abstract reports Dilept anxiety changes in cold, Noopept arithmetic-task findings in heat, and qualitative Cortexin work-capacity changes at simulated altitude.
Results and tables
Reported findings and study design
The abstract reports Dilept anxiety changes in cold, Noopept arithmetic-task findings in heat, and qualitative Cortexin work-capacity changes at simulated altitude.
86 healthy men aged 18–22, considered fit for military service; Tabai climate chamber with cold, heat and simulated altitude
Population or model 86 healthy men aged 18–22, considered fit for military service; Tabai climate chamber with cold, heat and simulated altitude
Protocol information
The conference abstract does not report doses, routes, timing or arm sizes. The 127-person journal report describes its own methods.
Protocol source ↗ · Entire original conference abstract checked in the proceedings PDF; no full study report or tables accompany it
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Dilept · cold exposure | State anxiety −24%; trait anxiety −19% | Percentages as reported; no arm sample size, baseline score or verified between-arm effect. |
| Noopept · heat exposure | Arithmetic errors reportedly fell to zero | The task denominator, absolute starting error count and placebo contrast were not supplied. |
| Noopept · cold and heat | Favorable self-rated functional state; less anxiety described | Different anxiety measures across conditions; no complete estimates. |
| Cortexin · simulated altitude | Higher work-capacity indices described | The conference abstract does not provide magnitudes or uncertainty. Psychological effects were described as smaller than with Dilept or Noopept. |
| Placebo comparator | Narrative and p-value conflict | “Did not differ” is accompanied by p<0.05. No correction inferred. |
The outcomes are condition-specific and largely qualitative. Use the journal record for its separate tables and route details, with possible cohort overlap kept visible.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- 86 healthy men aged 18–22, considered fit for military service; Tabai climate chamber with cold, heat and simulated altitude
- Source reviewed
- Entire original conference abstract checked in the proceedings PDF; no full study report or tables accompany it
Study limitations
- Treatment allocation, masking, arm denominators and complete comparator data unavailable.
- The text says placebo and control measurements did not differ while printing p<0.05; this inconsistency cannot be resolved from the abstract.
- This report may overlap the 2007 journal reports or 2008 dissertation. The 86 participants are listed separately and excluded from the combined total.
Reviewed 2026-11-08.
Animal research · 2009
Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and Cortexin
Separate comparisons in an assay battery.
Study notes and original source
Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and Cortexin
· Original journal article
Format: Publisher full-text methods and results narrative; original PDF tables not recovered · Reviewed: Reported methods, results and evidence limitations
P. D. Shabanov et al. · Medical Academic Journal, 2009; publisher article 9357
Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.
Results and tables
Reported findings and study design
Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.
192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
Population or model 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
Dose, route and schedule
Intraperitoneal doses: 1 mg/kg Cortexin, Cerebrolysin, Cortagen, Oleyl-Cortagen, Noopept and Dilept; 0.1 mg/kg Deltaran, Semax and Selank; piracetam 200 mg/kg. General behavior tests 30–40 minutes post-dose; self-stimulation measured 15–20 minutes post-dose.
Protocol source ↗ · Publisher full-text methods and results narrative; original PDF tables not recovered
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Oleyl-Cortagen · self-stimulation | +32% in lateral-hypothalamic pedal presses | Reported relative increase, not an endurance or strength endpoint. |
| Cortexin · self-stimulation | +23% in lateral-hypothalamic pedal presses | Reported relative increase; no direct statistical test versus Oleyl-Cortagen supplied in narrative. |
| Cortagen and Cerebrolysin · self-stimulation | No change reported in pedal-press frequency | At the systemic doses in this article; does not contradict the separate central-dose comparisons. |
| Open-field behavior | Oleyl-Cortagen increased horizontal and vertical movement but halved hole exploration | Cortexin and Cerebrolysin increased horizontal movement; Dilept reduced horizontal and vertical movement. |
| Noopept, Semax, Selank and Dilept · vertical activity | Reduced vertical movements reported | Compound-specific rat behavior at the stated doses, not a measure of human alertness. |
| Porsolt immobility | Lower with Oleyl-Cortagen, Dilept and Cortexin; higher with Cerebrolysin, Semax, Cortagen and Selank | This unweighted behavior assay is distinct from loaded endurance swimming. Piracetam was inactive in the report. |
| Deltaran · grooming | Grooming reactions increased | The report tested Deltaran, a DSIP-containing formulation; this observation is not assigned to isolated DSIP. |
Opposing effects across assays are informative. Electrical self-stimulation and immobility are behavior readouts, and neither establishes improved human motivation or endurance.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- 192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
- Source reviewed
- Publisher full-text methods and results narrative; original PDF tables not recovered
Study limitations
- Multiple behavioral comparisons, endpoint-specific group sizes and precise uncertainties need table recovery.
- Deltaran is the tested DSIP-containing formulation; no result for isolated DSIP can be inferred.
- The 2015 dissertation used separate doses/routes; it is not confirmed as independent replication of every experiment.
Reviewed 2026-11-08.
Experiment described in a patent · 2011
Dilept: defined peptide-derived formulation — RU2420304C2
The patent reports producing solid dosage forms that meet stated quality requirements.
Study notes and original source
Dilept: defined peptide-derived formulation — RU2420304C2
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Сергей Борисович Середенин (RU), Сергей Борисович Середенин, Борис Михайлович Пятин (RU), Борис Михайлович Пятин, Нина Ивановна Авдюнина (RU), Нина Ивановна Авдюнина, Константин Викторович Алексеев (RU), Константин Викторович Алексеев, Любовь Николаевна Грушевская (RU), Любовь Николаевна Грушевская, Евгения Викторовна Блынская (RU), Евгения Викторовна Блынская, Раиса Филипповна Большакова (RU), Раиса Филипповна Большакова, Максим Владимирович Гусев (RU), Максим Владимирович Гусев, Ольга Михайловна Шендера (RU), Ольга Михайловна Шендера · RU2420304C2 · patent family 42685698
The patent reports producing solid dosage forms that meet stated quality requirements.
Results and tables
Reported patent results
Findings described in words
The patent reports producing solid dosage forms that meet stated quality requirements.
Dilept formulation/process examples and pharmacopoeial quality specifications; no clinical antipsychotic comparison.
Population or model Dilept formulation/process examples and pharmacopoeial quality specifications; no clinical antipsychotic comparison.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Formulation outcome | Example tablets/capsules are reported to meet pharmacopoeial requirements | A manufacturing claim supported by preparation examples, not a clinical response |
| Quality specifications | Capsule disintegration limit ≤20 minutes; impurity limits ≤0.5% individually and ≤1% total | These are acceptance limits, not measured patient outcomes or observed batch values |
The table reports product specifications. Actual batch measurements are not independently extracted here.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Dilept formulation/process examples and pharmacopoeial quality specifications; no clinical antipsychotic comparison.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- Exact chemical identity matters; the formulation patent does not establish comparative antipsychotic efficacy.
- The table reports product specifications. Actual batch measurements are not independently extracted here.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Observational study · 2020
[The peptide analogue of neurotensin with antipsychotic and pro-cognitive effects: results of the pilot clinical trial].
A 25-person Dilept pilot reported psychiatric and cognitive improvement, most evident at 200 mg/day; it did not provide numerical symptom-score changes in its abstract.
Study notes and original source
[The peptide analogue of neurotensin with antipsychotic and pro-cognitive effects: results of the pilot clinical trial].
Neznamov GG, Bogdanova IO, Sunyakov TS, Dorofeeva OA, Kovalenok TV, Chepeluk AA · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
A 25-person Dilept pilot reported psychiatric and cognitive improvement, most evident at 200 mg/day; it did not provide numerical symptom-score changes in its abstract.
Results and tables
Reported findings and study design
A 25-person Dilept pilot reported psychiatric and cognitive improvement, most evident at 200 mg/day; it did not provide numerical symptom-score changes in its abstract.
25 patients with schizotypal disorder; 14-day monotherapy phase with limited rescue phenazepam, followed by combination treatment if needed.
Dose, route and schedule
Dilept: 60, 120 or 200 mg/day for 14 days as monotherapy. Single 2 mg doses of phenazepam were permitted as rescue treatment; subsequent combination treatment must be distinguished from the monotherapy phase.
Protocol source ↗ · Indexed publication abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Psychiatric and cognitive measures | Reported favorable changes; no PANSS, CGI or WAIS-R deltas supplied | |
| Participants | 25; mean age 33.4 ± 10.0 years | |
| Studied doses | 60, 120 and 200 mg/day; strongest reported action at 200 mg/day |
Small uncontrolled pilot with rescue and subsequent combination therapy; claims about superiority to other antipsychotics are not established by this design.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 25 patients with schizotypal disorder
- Source reviewed
- Original full paper and 2017 dose-finding publication, with cohort comparison.
Study limitations
- Small pilot with permitted or add-on phenazepam. The same 25 patients are described in the 2017 cognitive report. The 2021 active comparison may reuse the 15-person high-dose arm.
Reviewed 2026-11-15.
Animal research · 2013
[The study of procognitive effect of the potential antipsychotic, Dilept and its main metabolite, GZR-125 at the novel objects recognition test in rats].
Dilept and its metabolite GZR-125 were compared in rat novel-object recognition experiments, extending the neurotensin-mimetic program beyond the parent compound.
Study notes and original source
[The study of procognitive effect of the potential antipsychotic, Dilept and its main metabolite, GZR-125 at the novel objects recognition test in rats].
Gorelov PI, Ostrovskaia RU, Sazonova NM · Eksperimental'naia i klinicheskaia farmakologiia
Dilept and its metabolite GZR-125 were compared in rat novel-object recognition experiments, extending the neurotensin-mimetic program beyond the parent compound.
- Population / setting
- Rats; experimental object recognition
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Animal research · 2013
[Neurotensin NT (8- 13) dipeptide analog dilept increases the pain threshold and decreases the severity of morphine withdrawal syndrome in rats].
Dilept increased experimental pain thresholds and reduced morphine-withdrawal signs in rats. These findings are distinct from its small psychiatric pilot and occupational comparisons.
Pain threshold · 34% increase · p<0.01
Study notes and original source
[Neurotensin NT (8- 13) dipeptide analog dilept increases the pain threshold and decreases the severity of morphine withdrawal syndrome in rats].
Konstantinopol'skiĭ MA, Cherniakova IV, Kudrin VS, Klodt PM, Kolik LG, Gudasheva TA · Eksperimental'naia i klinicheskaia farmakologiia
Dilept increased experimental pain thresholds and reduced morphine-withdrawal signs in rats. These findings are distinct from its small psychiatric pilot and occupational comparisons.
Results and tables
Reported findings and study design
Rat tail-flick and morphine-withdrawal experiments; Dilept 1.6 mg/kg IP. Dependence induced with morphine 10–20 mg/kg IP for five days; 16 withdrawal signs scored.
Population or model Rats; experimental pain and morphine withdrawal
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Pain threshold | 34% increase | p<0.01 |
| Withdrawal expression after single Dilept administration | 29.1% reduction | p<0.01 |
| Withdrawal expression after subchronic administration | 37.5% reduction | p<0.01 |
| Morphine analgesia | No change with Dilept reported |
Rat outcomes; not a human addiction-treatment regimen.
Source for these results ↗ · Reviewed 2026-10-29
- Population / setting
- Rats; experimental pain and morphine withdrawal
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Preclinical findings do not establish human benefit or safety.
- Abstract only. Full methods and independent replication remain unconfirmed.
Reviewed 2026-10-05.
Review of earlier studies · 2018
Novel Technologies for Dipeptide Drugs Design and their Implantation.
The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.
Study notes and original source
Novel Technologies for Dipeptide Drugs Design and their Implantation.
Gudasheva TA, Ostrovskaya RU, Seredenin SB · Current pharmaceutical design
The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.
- Population / setting
- Developer account of medicinal-chemistry programs
- Source reviewed
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
- Developer review; claims require appraisal of each original study.
- A shared design method does not establish equivalent biology or clinical benefit.
Reviewed 2026-10-05.
Controlled study in people · 2007
Meteoadaptogenic properties of peptide drugs in healthy volunteers
A program involving 127 healthy men compared four preparations under cold, heat and simulated altitude. Results varied by compound and test.
Study notes and original source
Meteoadaptogenic properties of peptide drugs in healthy volunteers
Format: Original journal PDF · Reviewed: Original publisher PDF, printed pages 42–44: legacy Cyrillic text decoded and selected results rows checked; visual table appraisal remains open
P. D. Shabanov, V. P. Ganapolsky, P. V. Aleksandrov · Eksp Klin Farmakol. 70(6):41–47
Noopept showed different performance and anxiety results under cold, heat and simulated altitude. The tables also distinguish Cortexin, Dilept and Vinpotropil.
Results and tables
Reported findings and study design
Noopept showed different performance and anxiety results under cold, heat and simulated altitude. The tables also distinguish Cortexin, Dilept and Vinpotropil.
127 healthy men across the program; active subgroups 10–20 and placebo 8–10 per stage. Program size is not the number given Noopept. Cold −10°C, heat +45°C and simulated altitude 3,000 m.
Population or model 127 healthy men aged 20–24 across a three-day environmental program; active groups reported as 10–20, placebo 8–10 per stage
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Noopept PWC170 in cold | 189 ± 10 versus 162 ± 2 | Placebo comparison in the cold chamber; source PWC170 values, units not added · Cold chamber · Source marks p<0.05 versus placebo and historical control |
| Noopept PWC170 in heat | 188 ± 6 versus 152 ± 1 | Placebo in the heat chamber; values checked in Table 2 · Heat chamber · Source marks p<0.05 versus placebo and historical control |
| Noopept arithmetic errors in heat | 0 ± 0 versus 0.8 ± 0.2 | Placebo in the heat chamber; test-specific errors · Heat chamber · Source significance marker versus placebo and historical control |
| Noopept state / trait anxiety in heat | 27 ± 3 / 27 ± 2 | Historical controls: 38 ± 2 / 34 ± 3; retain separate comparison identities · Heat chamber · Source marks p<0.05 versus placebo and historical control |
| Noopept PWC170 at simulated altitude | 197 ± 8 versus 154 ± 3 | Concurrent placebo; source values · Simulated 3,000 m · Source marks p<0.05 versus placebo and historical control |
| Noopept activity self-rating in heat | 5.9 ± 0.4 versus 4.2 ± 0.2 | Historical no-drug controls; the placebo value is separately shown in the table · Heat chamber |
Cold chamber (−10°C): selected reported rows
| Setting | Preparation | Grip strength, kg | PWC170 | Max oxygen uptake, L | Arithmetic actions | Arithmetic errors | State anxiety | Trait anxiety | Well-being | Activity | Mood |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Before chamber | Historical no-drug control | 46 ± 5 | 153 ± 7 | 1.5 ± 0.01 | 10.5 ± 1.2 | 1.2 ± 0.8 | 33 ± 3 | 31 ± 4 | 5.6 ± 0.3 | 4.9 ± 0.2 | 5.5 ± 0.5 |
| Before chamber | Cortexin | 42 ± 1b | 155 ± 1b | 1.5 ± 0.001 | 9.3 ± 1.7 | 1.5 ± 0.6 | 33 ± 3 | 31 ± 4 | 5.6 ± 0.4 | 5.3 ± 0.3 | 5.7 ± 0.5 |
| Before chamber | Vinpotropil | 44 ± 3 | 219 ± 9ab | 1.6 ± 0.01ab | 10.5 ± 1.0 | 2.1 ± 0.9 | 35 ± 3 | 32 ± 3 | 5.1 ± 0.3 | 5.0 ± 0.2 | 4.8 ± 0.5 |
| Before chamber | Noopept | 46 ± 3 | 189 ± 3ab | 1.6 ± 0.01ab | 9.2 ± 1.2 | 0.4 ± 0.2 | 28 ± 2a | 27 ± 2 | 6.0 ± 0.9 | 6.3 ± 0.8 | 6.2 ± 0.7 |
| Before chamber | Dilept | 42 ± 1b | 176 ± 1ab | 1.5 ± 0.02 | 10.8 ± 1.8 | 0.8 ± 0.4 | 28 ± 2a | 28 ± 3 | 6.2 ± 0.7 | 5.4 ± 0.7 | 5.8 ± 0.3 |
| Before chamber | Placebo | 48 ± 2 | 159 ± 3 | 1.5 ± 0.01 | 9.7 ± 0.7 | 1.2 ± 0.6 | 31 ± 4 | 31 ± 3 | 5.6 ± 0.2 | 5.2 ± 0.3 | 5.6 ± 0.4 |
| In chamber | Historical no-drug control | 45 ± 5 | 165 ± 7 | 1.5 ± 0.01 | 9.8 ± 1.9 | 2.5 ± 0.4 | 38 ± 2 | 34 ± 3 | 5.0 ± 0.1 | 4.2 ± 0.2 | 5.4 ± 0.4 |
| In chamber | Cortexin | 45 ± 3 | 210 ± 7ab | 1.6 ± 0.02ab | 11.0 ± 1.9 | 0.3 ± 0.3ab | 38 ± 4 | 31 ± 4 | 5.2 ± 0.3 | 4.7 ± 0.4 | 5.1 ± 0.4 |
| In chamber | Vinpotropil | 45 ± 2 | 219 ± 13ab | 1.6 ± 0.02ab | 7.5 ± 0.8b | 0.5 ± 0.2ab | 36 ± 2 | 28 ± 3a | 4.9 ± 0.3b | 4.9 ± 0.1 | 5.1 ± 0.3 |
| In chamber | Noopept | 44 ± 2 | 189 ± 10ab | 1.6 ± 0.02ab | 10.6 ± 1.5 | 1.6 ± 0.6 | 30 ± 3a | 27 ± 3a | 5.3 ± 0.3 | 6.0 ± 1.1a | 6.4 ± 0.8 |
| In chamber | Dilept | 41 ± 1ab | 182 ± 5ab | 1.7 ± 0.01ab | 10.8 ± 1.9 | 0.8 ± 0.4a | 29 ± 3a | 28 ± 3a | 5.9 ± 0.5a | 5.3 ± 0.3a | 5.4 ± 0.6 |
| In chamber | Placebo | 47 ± 2 | 162 ± 2 | 1.5 ± 0.01 | 10.0 ± 0.6 | 1.2 ± 0.5 | 33 ± 3 | 32 ± 3 | 5.4 ± 0.2 | 5.1 ± 0.4 | 5.5 ± 0.3 |
Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.
Heat chamber (+45°C): selected reported rows
| Setting | Preparation | Grip strength, kg | PWC170 | Max oxygen uptake, L | Arithmetic actions | Arithmetic errors | State anxiety | Trait anxiety | Well-being | Activity | Mood |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Before chamber | Historical no-drug control | 47 ± 3 | 161 ± 4 | 1.5 ± 0.01 | 10.5 ± 1.0 | 1.2 ± 0.8 | 33 ± 2 | 31 ± 4 | 5.6 ± 0.3 | 4.9 ± 0.2 | 5.5 ± 0.5 |
| Before chamber | Cortexin | 43 ± 2 | 181 ± 5ab | 1.6 ± 0.01ab | 11.5 ± 1.6 | 0.67 ± 0.2 | 35 ± 3 | 32 ± 3 | 5.1 ± 0.3 | 4.9 ± 0.2 | 4.8 ± 0.5 |
| Before chamber | Vinpotropil | 45 ± 2 | 189 ± 9ab | 1.6 ± 0.02ab | 10.7 ± 1.0 | 0.9 ± 0.4 | 29 ± 3 | 26 ± 3 | 5.9 ± 0.3 | 5.8 ± 0.2ab | 5.9 ± 0.3 |
| Before chamber | Noopept | 48 ± 3 | 182 ± 3ab | 1.6 ± 0.01ab | 9.6 ± 1.3 | 0.8 ± 0.4 | 28 ± 3a | 27 ± 3 | 6.1 ± 0.2a | 6.1 ± 0.3ab | 6.4 ± 0.3ab |
| Before chamber | Dilept | 44 ± 2 | 180 ± 7ab | 1.6 ± 0.01ab | 9.7 ± 1.8 | 0.7 ± 0.2 | 26 ± 3ab | 28 ± 3 | 5.4 ± 0.2 | 4.6 ± 0.5b | 4.9 ± 0.2 |
| Before chamber | Placebo | 46 ± 2 | 164 ± 2 | 1.5 ± 0.01 | 11.0 ± 0.6 | 1.0 ± 0.1 | 32 ± 3 | 30 ± 3 | 5.5 ± 0.2 | 5.3 ± 0.2 | 5.5 ± 0.5 |
| In chamber | Historical no-drug control | 47 ± 4 | 151 ± 5 | 1.5 ± 0.01 | 9.8 ± 1.9 | 2.5 ± 0.4 | 38 ± 2 | 34 ± 3 | 5.0 ± 0.1 | 4.2 ± 0.2 | 5.4 ± 0.4 |
| In chamber | Cortexin | 39 ± 1a | 155 ± 9 | 1.5 ± 0.02 | 9.6 ± 1.1 | 0.8 ± 0.7a | 36 ± 2 | 28 ± 3a | 4.9 ± 0.3 | 4.9 ± 0.1a | 5.1 ± 0.3 |
| In chamber | Vinpotropil | 41 ± 2a | 202 ± 11ab | 1.6 ± 0.02ab | 10.3 ± 1.1 | 0.7 ± 0.4a | 31 ± 3 | 27 ± 3ab | 5.7 ± 0.2ab | 5.6 ± 0.2ab | 5.9 ± 0.3b |
| In chamber | Noopept | 44 ± 3 | 188 ± 6ab | 1.6 ± 0.01ab | 12.0 ± 1.4 | 0 ± 0ab | 27 ± 3ab | 27 ± 2ab | 6.2 ± 0.3ab | 5.9 ± 0.4ab | 6.2 ± 0.2ab |
| In chamber | Dilept | 42 ± 2 | 174 ± 9ab | 1.5 ± 0.01ab | 10.5 ± 0.9 | 0.8 ± 0.5a | 27 ± 3ab | 28 ± 2ab | 5.1 ± 0.3 | 4.6 ± 0.2a | 4.9 ± 0.2 |
| In chamber | Placebo | 42 ± 4 | 152 ± 1 | 1.5 ± 0.01 | 10.9 ± 1.3 | 0.8 ± 0.2 | 34 ± 3 | 33 ± 3 | 5.3 ± 0.2 | 4.9 ± 0.3 | 5.3 ± 0.2 |
Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.
Simulated altitude (3,000 m): selected reported rows
| Setting | Preparation | Grip strength, kg | PWC170 | Max oxygen uptake, L | Arithmetic actions | Arithmetic errors | State anxiety | Trait anxiety | Well-being | Activity | Mood |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Before chamber | Historical no-drug control | 46 ± 5 | 151 ± 4 | 1.3 ± 0.01 | 10.5 ± 1.0 | 1.2 ± 0.8 | 33 ± 2 | 31 ± 4 | 5.6 ± 0.3 | 4.9 ± 0.2 | 5.5 ± 0.5 |
| Before chamber | Cortexin | 42 ± 2 | 170 ± 5a | 1.6 ± 0.01ab | 9.7 ± 0.6 | 0.2 ± 0.12 | 34 ± 3 | 32 ± 3 | 5.6 ± 0.3 | 5.1 ± 0.2 | 5.5 ± 0.3 |
| Before chamber | Vinpotropil | 46 ± 2 | 195 ± 5ab | 1.6 ± 0.01ab | 9.0 ± 0.5 | 0.5 ± 0.2 | 28 ± 3 | 27 ± 3 | 6.1 ± 0.2ab | 6.1 ± 0.3ab | 6.4 ± 0.3ab |
| Before chamber | Noopept | 47 ± 3 | 202 ± 3ab | 1.6 ± 0.01ab | 11.2 ± 0.6 | 0.2 ± 0.2 | 29 ± 3 | 26 ± 2 | 5.9 ± 0.3 | 5.8 ± 0.2a | 5.9 ± 0.3 |
| Before chamber | Dilept | 41 ± 1 | 181 ± 3ab | 1.6 ± 0.01ab | 14.2 ± 3.0 | 1.0 ± 0.6 | 27 ± 3a | 28 ± 2 | 6.2 ± 0.2ab | 5.8 ± 0.1a | 5.8 ± 0.2 |
| Before chamber | Placebo | 46 ± 4 | 162 ± 5 | 1.5 ± 0.01 | 10.1 ± 0.8 | 0.6 ± 0.1 | 33 ± 3 | 30 ± 3 | 5.5 ± 0.2 | 5.6 ± 0.2 | 5.6 ± 0.4 |
| In chamber | Historical no-drug control | 46 ± 4 | 145 ± 5 | 1.3 ± 0.01 | 9.8 ± 1.9 | 3 ± 0.6 | 38 ± 2 | 34 ± 3 | 5.0 ± 0.1 | 4.2 ± 0.2 | 5.4 ± 0.4 |
| In chamber | Cortexin | 41 ± 2 | 170 ± 6ab | 1.6 ± 0.01ab | 9.7 ± 0.6 | 0.2 ± 0.2a | 34 ± 3 | 32 ± 3 | 5.4 ± 0.2 | 5.0 ± 0.2ab | 5.4 ± 0.2 |
| In chamber | Vinpotropil | 44 ± 2 | 196 ± 6ab | 1.6 ± 0.01ab | 10.4 ± 0.9 | 0.8 ± 0.3a | 27 ± 3ab | 27 ± 2ab | 6.2 ± 0.3ab | 5.9 ± 0.4ab | 6.2 ± 0.2ab |
| In chamber | Noopept | 45 ± 3 | 197 ± 8ab | 1.6 ± 0.01ab | 11.4 ± 1.7 | 2.2 ± 2.2 | 31 ± 4a | 27 ± 3ab | 5.7 ± 0.2a | 5.6 ± 0.2ab | 5.9 ± 0.3 |
| In chamber | Dilept | 41 ± 1 | 186 ± 6ab | 1.6 ± 0.01ab | 12.6 ± 2.5 | 0.6 ± 0.4a | 28 ± 3a | 28 ± 3ab | 6.3 ± 0.2ab | 5.6 ± 0.3ab | 6.1 ± 0.3ab |
| In chamber | Placebo | 46 ± 4 | 154 ± 3 | 1.5 ± 0.01 | 9.5 ± 1.0 | 0.6 ± 0.2 | 33 ± 3 | 34 ± 3 | 5.4 ± 0.3 | 4.6 ± 0.1 | 5.6 ± 0.2 |
Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.
Pre-chamber group differences, historical controls and unclear allocation limit attribution. The preparation-specific rows cannot be applied interchangeably to all four compounds. Experimental formulations and short chamber tasks do not establish safe performance during dangerous work.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 127 healthy men aged 20–24 across a three-day environmental program; active groups reported as 10–20, placebo 8–10 per stage
- Source reviewed
- Previously reviewed original journal PDF methods and selected tables. The separately recovered 86-man proceedings abstract is related; participant overlap remains unresolved.
Study limitations
- Random allocation and blinding not established; historical controls and baseline differences limit attribution.
- Exact arm-by-environment denominators remain unresolved; 127 is the program total, not Noopept enrollment.
- Experimental intranasal peptide preparations are not equivalent to marketed oral products.
- No validated protection from heat illness, operational accidents or long-term harm.
- The Academy report may cover the same participants.
Reviewed 2026-11-08.
Comparison in people · 2007
Meteoadaptogenic properties of nootrop drugs
The Academy abstract describes stressor-specific functional-state findings across four compounds, including Noopept. It emphasizes mental work capacity and heat/high-altitude adaptation.
Study notes and original source
Meteoadaptogenic properties of nootrop drugs
V. P. Ganapolsky, A. A. Elistratov, P. V. Alexandrov, P. D. Shabanov, E. G. Mokeeva, E. A. Mitin, V. I. Kruglov · Bulletin of the Russian Military Medical Academy. No. 4:61–66; date discrepancy noted
The Academy abstract describes stressor-specific functional-state findings across four compounds, including Noopept. It emphasizes mental work capacity and heat/high-altitude adaptation.
Results and tables
Reported findings and study design
Qualitative, stressor-specific comparisons.
Academy report on cold, heat and hypobaric hypoxia, with cohort overlap unresolved.
Population or model Healthy men aged 20–24; −10°C, +45°C and hypoxia (reported pO₂ 109.9 mmHg)
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Noopept | Favorable psychological measures in heat and cold; physical efficiency reported in heat | No effect sizes in the publisher abstract. |
| Cortexin and Vinpotropil | Cortexin effects described in cold and hypoxia; Vinpotropil in cold and heat | Distinct preparations and endpoints. |
| Dilept | Favorable psychological functional-state measures described | No numerical comparison or group counts in the abstract. |
Related to the 86-man and 127-man reports. Avoid pooling or importing their doses and estimates.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Healthy men aged 20–24; −10°C, +45°C and hypoxia (reported pO₂ 109.9 mmHg)
- Source reviewed
- Publisher metadata and Russian abstract checked. A related manufacturer-hosted PDF is indexed, but direct download timed out; the PDF contents were not appraised.
Study limitations
- The current publisher record says 2007, issue 4, pp. 61–66; later bibliographies cite 2008. Original issue verification remains open.
- This abstract differs from the Eksp Klin Farmakol summary, including the Cortexin/cold account. Differences are preserved pending table-level review.
- Possible cohort overlap with the 2007 paper; not independent replication.
Reviewed 2026-09-29.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗